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Aim: To study the nature of different variants of paraneoplastic syndrome (PNPS) in lung cancer, taking into account the features 
of the tumorous process and the complications of radiochemotherapy. Patients and Methods: We performed an analysis of the data 
of 1,669 patients with lung cancer aged between 24 and 87 years, among whom there were 89% of men and 11% of women. The ratio 
of small cell and non-small-cell histological variants of the lung cancer was 1: 4, IB, IIA, IIB, IIIA, IIIB and IV stages of cancer — 
1:2:6:58:43:57. Results: PNPS developed in 16% of the lung cancer patients, in these patients we have detected a marked increase 
in the disease incidence in women, the peripheral form of the tumor, the apical variant of Pancoast — Tobias and adenocarcinoma, 
but no cases of the median lower localization of the tumor. The number of the upper lobar pathology was decreased, while the se-
verity of the cancer was significantly greater, which more often occurred with exudative pleurisy, germination of the tumor into the 
chest wall and compression of the upper vena cava. The 21 components of PNPS pathology were established. We distributed them 
conditionally into the musculoskeletal system lesions, variants of skin vasculitis and autoimmune processes, the nature of which 
depended on the localization and course of the tumorous process, its histological variation and severity of the course. Moreover, 
PNPS negatively affected the development of radiochemotherapy complications and worsened survival rate. Conclusions: The course 
of PNPS in lung cancer is highly diverse, being a risk factor for a severe tumorous process that worsens the survival of patients.
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Lung cancer (LC) has the leading position 
in the structure of oncological morbidity, resulting 
in annual mortality increase in an average of 10% 
in some regions [1–3]. LC (especially its small cell 
histological variant and adenocarcinoma) is the most 
common cause of the so-called paraneoplastic syn-
drome (PNPS) development [4], which is not directly 
related to the primary neoplasm and its metastases, 
but it is due to the complex immune-inflammatory, 
degenerative and vascular distant changes [5, 6]. 
The study of the PNPS course peculiarities in LC has 
become one of the most urgent modern oncology 
problems [7].
PNPS, as a rule, proceeds with rheumatological, 
dermatological, endocrinological, neurological and 
nephrological manifestations [8–11]. Miret et al. [12] 
found that autoimmune paraneoplastic disorders oc-
curred in patients with non-small cell and small cell 
LC in a ratio of 1:9. Osteoarthropathy, arthritis, myo-
sitis and other autoimmune syndromes occur in 15% 
of the LC patients [13], more often in patients with 
bone metastases [14]. It should be noted that the suc-
cessful treatment of LC (surgical, radiochemotherapy) 
may be accompanied by the disappearance of PNPS 
signs [15]. The prognostic value of the latter in patients 
with LC remains inadequate studied [16, 17].
The aim of this study was to evaluate the nature 
of different PNPS variants in LC, taking into account 
the peculiarities of the tumor process course and the 
radiochemotherapy complications.
PATIENTS AND METHODS
The work was performed in accordance with the 
ethical standards set forth in the Declaration of the 
Helsinki Medical Assembly, and the patients gave their 
informed consent to a study approved by the Donetsk 
National Medical University Bioethics Commission.
The material of 4 oncological Ukrainian centers was 
retrospectively analyzed. There were 1669 patients 
with LC aged from 24 to 87 (59.4 ± 0.24 years on aver-
age), among whom 88.8% were men and 11.2% were 
women. Right-sided localization of the cancer process 
occurred in 56.9% of the patients, left-sided — 41.8%, 
bilateral — 1.3%. The upper lobe LC was diagnosed 
in 28.6% of the cases, the middle-upper lobe — 
21.3%, the left upper lower lobe — 20.2%, the lower 
lobe — 13.1%, the mediastinal — 11.0%, the median 
lobe — 2.9%, the median lower lobe — 1.7%. The small 
cell histological variant of the disease was diagnosed 
in 18.5% of the observations, and non-small-cell — 
in 81.6%, among which adenocarcinoma was detected 
in 37.2% of the total number of the examined patients 
and in 45.6% of the non-small cell form, squamous 
cell carcinoma — in 35.2% and 43.2%, respectively, 
large-cell carcinoma — in 9.2 and 11.2%.
IB stage of the disease was detected in 0.6% 
of LC cases, IIA — 1.3%, IIB — 3.6%, IIIA — 34.8%, 
IIIB — 25.9%, IV — 33.9%. The average index of LC dif-
ferentiation (GDT) was 1.160 ± 0.030 points, the inte-
gral stage index (StT) was 5.850 ± 0.025 r.u., the tumor-
ous process severity index (SI) was 2.850 ± 0.019 a.u., 
which was estimated by the formula: 
SI = ln [T + N2 + (SM)2], 
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where ln is a natural logarithm; T is an international 
indicator of the primary tumor extent; N is the interna-
tional index of regional lymph nodes metastatic lesion; 
SМ is the sum of metastases in distant organs.
Among the manifestations of LC, plevral exudates 
were observed in 9.7% of patients, compression syn-
drome — in 7.5%, the germination of the tumor into 
the trachea — in 6.8%, into the ribs — in 2.8%, into the 
chest — in 2.5%, into the esophagus — in 2.3% and 
into the pericardium — in 0.8%; 4.0% of the patients 
had obstructive atelectasis; 3.1% had the compression 
of the recurrent nerve; and 1.6% — the upper vena 
cava compression. Metastases to the lymph nodes 
were found in 81.1% of LC cases, metastases in distant 
organs — in 30.7%, in the skeleton — in 20.0%. For the 
diagnosing of the disease we used such apparatus as 
“Multix-Compact-Sièmens” (Germany), “Somazom-
Emotion-6-Siemens” (Germany), “Gygoscan-Intera-
Philips” (Netherlands), “Siemens-RDS-Eclipse-RD” 
cyclotron (Germany), “Olympus-GIF-Q20” (Japan) fiber-
scope and “Envisor-Philips” (Netherlands) sonograph.
Statistical processing of the obtained results was 
performed using computer variance, nonparametric, 
correlation, regression, single (ANOVA) and multivari-
ate (ANOVA/MANOVA) dispersion analysis (Microsoft 
Excel and Statistica-Stat-Soft, USA programs). We es-
timated the average values (M), their standard errors 
and deviations (SD), the parametric correlation coef-
ficients of Pearson and the nonparametric of Kendall, 
the criteria of Brown — Forsythe and Wilcoxon — Rao 
dispersion, Student and McNemar — Fisher’s test (χ2), 
and the reliability of the statistical indices (p). The 
critical significance level for checking the statistical 
hypotheses was considered to be 0.05.
In assessing the results of radiochemotherapy, the 
treatment intensity (IRCT) was studied. Thus, the aver-
age dosages of drugs and radiation {< M + SD} were 
defined as minimum in 1 point, the dosages {M + SD ÷ 
М + 2SD} — as moderate in 2 points, {M + 2SD ÷ 
M + 3SD} — as high in 3 points and {> M + 3SD} — 
as very high in 4 points. The treatment intensity W was 
calculated by the formula: 
W = (a + b + c + d) / n, 
where a, b, c, d — the number of radiation zones 
or drugs in 1, 2, 3 and 4 points, respectively; n is the 
total number of radiation zones or the total number 
of used drugs.
RESULTS AND DISCUSSION
Among 1,669 examined patients with LC, the main 
(1st) group consisted of 258 (15.5%) patients aged 
from 24 to 79 years (58.6 ± 0.65 years old on average), 
in which certain signs of PNPS were revealed. The 
comparison group (2nd) comprised from the remaining 
1411 patients. In addition, the patients of the main 
group were divided into 3 subgroups — 10.4% of the 
total number and 67.1% of the number with PNPS 
associated with bone-articular system and periarticular 
tissue lesions (subgroup A); 4.7% and 30.6% patients, 
respectively — with different variants of skin vasculitis 
(subgroup B); and 4.7% and 30.2% — with systemic 
autoimmune processes (subgroup C).
The first group consisted of 79.9% men and 20.2% 
women, the 2nd — 90.4% men and 9.6% women. Thus, 
the ratio of men and women in the 1st group was 4:1, 
and in the 2nd — 9:1 (the differences were significant). 
The patients’ average age in these groups was slightly 
different. The 1st and 2nd groups were approximately the 
same on the frequency of the side lesions by the tumor 
process, while the ratio of the central and peripheral 
forms was 3:1 in the main group and 5:1 in the control 
group. In the group of the PNPS patients, there were 
no patients with a tumor process localizing in the right 
median lower lobe, but they were diagnosed apical Pan-
coast — Tobias LC 4.4 times as often. In this regard, the 
tumor of Panсoast — Tobias can be assumed to be a risk 
factor for the development of PNPS, and the prognosis-
favorable factor in this respect is tumor localization in the 
right median lower lobe. Patients of the main group have 
adenocarcinoma more often (8%). Patients of the 1st 
and 2nd groups did not differ by such histological forms 
of non-small cell LC as squamous and large-squamous.
Subgroup A consisted of 24.0% of the PNPS 
patients with Marie — Bamberger osteoarthropathy, 
22.9% — with gouty arthritis, 15.9% — with paraneo-
plastic rheumatoid-like reactive arthritis, 14.3% — with 
peripheral neuropathy, 5.8% — with palmar-plantar 
fibrositis and tendovaginitis respectively, 3,5% — 
with fasciitis and enthesopathy, 3.1% — with algo-
dystrophy. Subgroup B included 10.5% of patients 
with leukocytoclastic vasculitis, 10.1% — with pan-
niculitis and nodular erythema, 8.5% — with digital 
arteritis, 1.9% — with cryoglobulinemic vasculitis, 
and subgroup C — 12.4% with dermatopolymyositis, 
6.% with scleroderma-like syndrome, 4.7% — with 
lupus-like syndrome, 4.3% — with limbic encephalitis, 
3.9% — with glomerulonephritis (membranous, me-
sangiocapillary), 3.5% — with myasthenic Lambert — 
Eaton syndrome, 2.3% — with Kikuchi — Fujimoto 
necrotizing lymphadenitis syndrome, 1.9% — with 
Sjogren’s syndrome). For one patient with PNPS there 
were from 1 to 9 symptoms (on average 1.77 ± 0.090).
Patients in the main group had the significantly in-
creased StT (9%) and SI (¼) indices. At the same time 
(Table 1), the 1st group significantly differed from the 
2nd group by the higher frequency of exudative pleurisy 
(2.1 times), tumor growth into the thorax (3.2 times), 
and the compression of the upper vena cava (4.7 times).
According to Wilcoxon — Rao multivariate disper-
sion analysis, clinical signs of LC course influenced 
on the nature of PNPS. We selected those signs 
of LC clinical course that simultaneously had Brown — 
Forsyth and correlation Kendall dispersion relations 
with PNPS. It turned out that the number of constituent 
manifestations of PNPS rises with the age of LC pa-
tients, with an increase in the degree and severity of the 
disease course. All subgroups of patients with PNPS 
(A, B, C) are affected by the localization of the tumor 
process, the form of LC, the squamous histological 
variant, the parameters of StT and SI.
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According to Brown — Forsythe dispersion analy-
sis, the number of PNPS manifestations in one patient 
with LC is affected by the germination of the tumor 
into the esophagus, the chest wall, and the upper 
vena cava. In subgroup A, such an effect concerns the 
LC germination into the rib, in subgroup B — germina-
tion into the trachea, esophagus, thoracic wall and the 
upper vena cava; in subgroup C, PNPS is associated 
with the presence of exudative pleurisy and tumor 
germination into the pericardium.
PNPS in the form of the musculoskeletal system 
lesions has a dispersion and direct correlation with 
metastases into the skeleton, PNPS caused by autoim-
mune pathology — with metastases to distant organs. 
Among the concomitant diseases, the development 
of PNPS is closely related to the presence of chronic 
bronchitis, chronic obstructive pulmonary disease, 
diabetes mellitus, chronic gastroduodenitis and ulcers 
of the stomach and duodenum in patients with LC.
It should be noted that PNPS in LC patients may 
result from the chemotherapy complications [18], 
which primarily concerns platinum-based and taxane 
agents [19]. As shown by Brown — Forsythe disper-
sion analysis and Kendall nonparametric correlation, 
the power of the performed radiation therapy, the us-
age of 8 groups of drugs included in chemotherapy 
such as anti-metabolites (gemcitabine, methotrexate, 
pemetrexed, fluorouracil), vinca alkaloid (vinblastine, 
vincristine), anthracyclines (bleomycin, doxorubicin, 
idarubicin, mitomycin, epirubicin) have a direct nega-
tive effect on the formation of PNPS in LC.
It should be noted that in the main group of LC patients, 
the IRCT was 1.470 ± 0.054 and 0.400 ± 0.026 a.u., 
whereas in the PNPS absence, they were significantly 
less by 30% and 25% respectively. In 1st group, the 
number of PNPS signs was directly related to both the 
power of radiation and chemotherapy, as demonstrated 
by the dispersion and correlation analysis.
In the process of radiochemotherapy, myelode-
pression developed in 7.0% of cases, acute radiation 
pneumonitis — 3.0%, pulmonary hypertension — 
2.9%, radiation osteophagitis — 2.2%, acute coronary 
syndrome — 2.0%, radiation lung fibrosis and indomi-
table vomiting — 1.6%, acute tubulointerstitial nephri-
tis — 1.4%, stroke — 1.3%, acute thrombophlebitis — 
1.2%, persistent diarrhea — 0.8%, jaundice — 0,7%, 
pulmonary artery thromboembolism — 0.6% (Table 2).
The multivariate analysis of Wilcoxon — Rao demon-
strated the effect of the PNPS nature on the complica-
tions of radiochemotherapy. According to McNemar — 
Fisher non-parametric comparative analysis, in the 
presence of PNPS, pulmonary hypertension deve-
loped significantly 2.3 times, cerebral circulation le-
sion — 3.4 times, radiation pneumophilia — 3.6 times, 
jaundice — 4.8 times, thrombophlebitis — 7.8 times 
as often.
Table 2. The frequency of separate complications caused by therapeutic 
interventions (radiochemotherapy) in LC patients of the 1st and 2nd groups
LC signs
Patients groups Differences  
between the groups1st (n = 258) 2nd (n = 1411)
n % n % χ2 р
1
2
3
4
5
6
7
8
9
10
11
12
13
21
11
14
8
6
10
3
7
8
12
4
5
4
8.1
4.3
5.4
3.1
2.3
3.9
1.2
2.7
3.1
4.7
1.6
1.9
1.6
96
39
34
29
28
16
23
17
13
8
9
6
6
6.8
2.8
2.4
2.1
2.0
1.1
1.6
1.2
0.9
0.6
0.6
0.4
0.4
0.37
1.69
7.11
1.10
0.13
10.69
0.31
3.50
8.34
30.73
2.35
7.62
2.43
0.543
0.194
0.008
0.294
0.721
0.001
0.577
0.061
0.004
< 0.001
0.125
0.006
0.119
Note: 1 — myelodepression, 2 — acute radiation pneumonitis, 3 — pulmo-
nary hypertension, 4 — radiation esophagitis, 5 — acute coronary syndrome, 
6 — radiation pulmonary fibrosis, 7 — indomitable vomiting, 8 — acute tubu-
lointerstitial nephritis, 9 — stroke, 10 — acute thrombophlebitis, 11 — per-
sistent diarrhea, 12 — jaundice, 13 — pulmonary artery branches embolism.
The three-year survival indicators of the 1st group 
patients turned out to be worse (Figure) and all patients 
with PNPS died in 30 months. In deceased patients, 
life expectancy after diagnosis of LC was on average 
by 4 months less, being 10.8 ± 0.31 months. As shown 
by the dispersion analysis, the life span was influenced 
by the number of PNPS components in one such 
patient.
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Figure. Three-year survival rates of the patients from the 1st 
and 2nd groups
CONCLUSION
PNPS developed in 16% of the LC patients, in these 
patients we have detected a marked increase in the 
incidence of the disease in women, the peripheral form 
of the tumor, the Pancoast — Tobias apical variant and 
adenocarcinoma, but no cases of the median lower 
Table 1. Frequency of LC separate manifestations in patients 
of the 1st and 2nd groups
LC signs
Patients groups Differences between 
the groups1st (n = 258) 2nd (n = 1411)
n % n % χ2 р
1
2
3
4
5
6
7
8
9
10
44
18
6
21
4
15
2
8
12
12
17.1
7.0
2.3
8.1
1.6
5.8
0.8
3.1
4.7
4.7
117
107
60
92
34
26
12
38
14
39
8.3
7.6
4.3
6.5
2.4
1.8
0.9
2.7
1.0
2.8
19.21
0.12
2.13
0.91
0.72
14.36
0.01
0.14
19.04
2.62
< 0.001
0.734
0.144
0.341
0.395
< 0.001
0.903
0.713
< 0.001
0.105
Note: 1 — exudative pleurisy, 2 — compression syndrome, 3 — obturation at-
electasis, 4 — tumor germination into the trachea, 5 — tumor germination 
into the esophagus, 6 — tumor germination into the thoracic wall, 7 — tu-
mor germination into the pericardium, 8 — tumor germination into the rib, 
9 — tumor compression of the superior vena cava, 10 — tumor compression 
of the recurrent nerve.
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localization. The number of the upper lobar pathology 
was decreased, while the severity of the cancer was 
significantly greater, which more often occurred along 
with exudative pleurisy, germination of the tumor into 
the chest wall and compression of the upper vena 
cava. The 21 components of PNPS pathology were 
established, we distributed them conditionally into 
the musculoskeletal system lesions, variants of skin 
vasculitis and autoimmune processes, the nature 
of which depends on the localization and course of the 
tumorous process, its histological variation and course 
severity. Moreover, PNPS negatively affected the de-
velopment of radiochemotherapy complications and 
worsened survival rate.
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